We next evaluated the mean percentage of CD4+ and CD8+ T cells expressing ILT2 and found it to be significantly elevated in metastatic melanoma patients compared to healthy donors (n = 11 and 10-11, respectively; P = 0.002 and P = 0.0009, respectively; Figure 3B and C). This evidence concerns the gene LILRB1 and metastatic melanoma.